Latest News

According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...

According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.

According to results from the phase 3 NRG-GU003 trial, hypofractionated postprostatectomy radiotherapy did not significantly increase the likeliness of experiencing patient-reported genitourinary or gastrointestinal symptoms 1 to 2 years post...

The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...

Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.

Interim analysis results from the phase 3 RATIONALE-315 study demonstrated that neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab significantly improved survival benefit among patients with treatment-naïve, resectable,...

Crenolanib plus intensive chemotherapy demonstrated high rates of deep responses and long-term survival as well as tolerable safety among patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...